Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis

• Published in: International journal of molecular sciences Vol. 20; no. 23; p. 5936
• Main Authors: Wu, Yue, Xu, Ming-Jiang, Cao, Zhiyou, Yang, Chun, Wang, Jinjie, Wang, Bijue, Liu, Jian, Wang, Yuhui, Xian, Xunde, Zhang, Fang, Liu, George, Chen, Xiaoli
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.11.2019; MDPI
• Subjects: Abdomen; Animals; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Atherosclerosis; Atherosclerosis - chemically induced; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Cardiovascular disease; Cholesterol; Cholesterol, LDL - blood; Coronary vessels; Correlation analysis; Cricetinae; Diet, High-Fat - adverse effects; Disease Models, Animal; Ezetimibe - administration & dosage; Ezetimibe - pharmacology; Heterozygote; Humans; Hyperlipidemias - chemically induced; Hyperlipidemias - drug therapy; Hyperlipidemias - genetics; Lipids; Lipoproteins; Male; Metabolic disorders; Metabolism; Mutation; Plasma; Proprotein Convertase 9 - antagonists & inhibitors; Proteins; Receptors, LDL - deficiency; Treatment Outcome; Triglycerides; atherosclerosis; proprotein convertase subtilisin/kexin type 9; low-density lipoprotein receptor; animal model; dyslipidemia; low-density lipoprotein

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis and atherogenesis. However, there are only limited rodent models, with a functional low-density lipoprotein receptor (LDLR) pathway and cholesteryl ester transfer protein (CETP) to evaluate the drug can...